Discovery of N-(5-amido-2-methylphenyl)-5-methylisoxazole-3-carboxamide as dual CSF-1R/c-Kit Inhibitors with improved stability and BBB permeability
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Baek, Jihyun | - |
dc.contributor.author | Kim, Hyejin | - |
dc.contributor.author | Jun, Joonhong | - |
dc.contributor.author | Kang, Dahyun | - |
dc.contributor.author | Bae, Hyunah | - |
dc.contributor.author | Cho, Hyunwook | - |
dc.contributor.author | Hah, Jung-Mi | - |
dc.date.accessioned | 2024-04-01T08:30:31Z | - |
dc.date.available | 2024-04-01T08:30:31Z | - |
dc.date.issued | 2024-03 | - |
dc.identifier.issn | 0223-5234 | - |
dc.identifier.issn | 1768-3254 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/118338 | - |
dc.description.abstract | This study explores the potential of CSF-1R inhibitors as therapeutic agents for neurodegenerative diseases. CSF-1R, a receptor tyrosine kinase primarily expressed in macrophage lineages, plays a pivotal role in regulating various cellular processes. Recent research highlights the significance of CSF-1R inhibition in mitigating neuroinflammation, particularly in Alzheimer's disease, where microglial overactivation contributes to neurodegeneration. The research reveals a series of N-(5-amido-2-methylphenyl)-5-methylisoxazole-3-carboxamide CSF-1R inhibitors, where compounds 7d, 7e, and 9a exhibit outstanding inhibitory activities and selectivity, with IC50 values of 33, 31, and 64 nM, respectively. These most promising compounds in this series were profiled for cellular potency and subjected to in vitro pharmacokinetic profiling. These inhibitors exhibit minimal cytotoxicity, even at higher concentrations, and possess promising blood-brain barrier permeability, making them potential candidates for central nervous system diseases. The investigation into the in vitro ADME properties, including plasma and microsomal stability, reveals that these CSF-1R inhibitors maintain their structural integrity and plasma concentration. This resilience positions them for further development as therapeutic agents for neurodegenerative diseases. © 2024 Elsevier Masson SAS | - |
dc.format.extent | 13 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier Masson s.r.l. | - |
dc.title | Discovery of N-(5-amido-2-methylphenyl)-5-methylisoxazole-3-carboxamide as dual CSF-1R/c-Kit Inhibitors with improved stability and BBB permeability | - |
dc.type | Article | - |
dc.publisher.location | 프랑스 | - |
dc.identifier.doi | 10.1016/j.ejmech.2024.116253 | - |
dc.identifier.scopusid | 2-s2.0-85185914180 | - |
dc.identifier.wosid | 001198902600001 | - |
dc.identifier.bibliographicCitation | European Journal of Medicinal Chemistry, v.268, pp 1 - 13 | - |
dc.citation.title | European Journal of Medicinal Chemistry | - |
dc.citation.volume | 268 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 13 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.subject.keywordPlus | KINASE INHIBITOR | - |
dc.subject.keywordPlus | FMS | - |
dc.subject.keywordPlus | ISOXAZOLE | - |
dc.subject.keywordPlus | MASITINIB | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordAuthor | CSF-1R | - |
dc.subject.keywordAuthor | Methyloxazole | - |
dc.subject.keywordAuthor | Neurodegenerative diseases | - |
dc.subject.keywordAuthor | Neuroinflammation | - |
dc.subject.keywordAuthor | SAR | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0223523424001338?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.